Welcome!

News Feed Item

Spasticity Global Clinical Trials Review, H2, 2014

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Spasticity Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2280943/Spasticity-Global-Clinical-Trials-Review-H2-2014.html

Spasticity Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spasticity 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spasticity to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spasticity to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spasticity 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Spasticity Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Ipsen S.A. 35
Clinical Trial Overview of Ipsen S.A. 35
Merz Pharma GmbH & Co. KgaA 36
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 36
GW Pharmaceuticals plc 37
Clinical Trial Overview of GW Pharmaceuticals plc 37
GlaxoSmithKline plc 38
Clinical Trial Overview of GlaxoSmithKline plc 38
Sun Pharma Advanced Research Company 39
Clinical Trial Overview of Sun Pharma Advanced Research Company 39
MediciNova, Inc. 40
Clinical Trial Overview of MediciNova, Inc. 40
Acorda Therapeutics, Inc. 41
Clinical Trial Overview of Acorda Therapeutics, Inc. 41
Concert Pharmaceuticals, Inc. 42
Clinical Trial Overview of Concert Pharmaceuticals, Inc. 42
Almirall, S.A. 43
Clinical Trial Overview of Almirall, S.A. 43
Clinical Trial Overview of Top Institutes / Government 44
Vanderbilt University 44
Clinical Trial Overview of Vanderbilt University 44
National Institute of Neurological Disorders and Stroke 45
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 45
University of Minnesota 46
Clinical Trial Overview of University of Minnesota 46
University of Alberta 47
Clinical Trial Overview of University of Alberta 47
Eunice Kennedy Shriver National Institute of Child Health and Human Development 48
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 48
University of Manitoba 49
Clinical Trial Overview of University of Manitoba 49
Princess Margaret Hospital 50
Clinical Trial Overview of Princess Margaret Hospital 50
Center for Medicinal Cannabis Research 51
Clinical Trial Overview of Center for Medicinal Cannabis Research 51
Department of Health, UK 52
Clinical Trial Overview of Department of Health, UK 52
University Hospital of Mont-Godinne 53
Clinical Trial Overview of University Hospital of Mont-Godinne 53
Five Key Clinical Profiles 54
Appendix 117
Abbreviations 117
Definitions 117
Research Methodology 118
Secondary Research 118
About GlobalData 119
Contact Us 119
Disclaimer 119
Source 119

List of Tables

Spasticity Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spasticity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spasticity Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spasticity Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spasticity Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 33
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 35
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 36
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 37
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 38
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Pharma Advanced Research Company, 2014* 39
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by MediciNova, Inc., 2014* 40
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 41
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Concert Pharmaceuticals, Inc., 2014* 42
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Almirall, S.A., 2014* 43
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014* 44
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 45
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 46
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alberta, 2014* 47
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 48
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Manitoba, 2014* 49
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Princess Margaret Hospital, 2014* 50
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Center for Medicinal Cannabis Research, 2014* 51
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 52
Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital of Mont-Godinne, 2014* 53

List of Figures

Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spasticity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 118


Read the full report:
Spasticity Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2280943/Spasticity-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Containers, microservices and DevOps are all the rage lately. You can read about how great they are and how they’ll change your life and the industry everywhere. So naturally when we started a new company and were deciding how to architect our app, we went with microservices, containers and DevOps. About now you’re expecting a story of how everything went so smoothly, we’re now pushing out code ten times a day, but the reality is quite different.
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, will outline ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The hierarchical architecture that distributes "compute" within the network specially at the edge can enable new services by harnessing emerging technologies. But Edge-Compute comes at increased cost that needs to be managed and potentially augmented by creative architecture solutions as there will always a catching-up with the capacity demands. Processing power in smartphones has enhanced YoY and there is increasingly spare compute capacity that can be potentially pooled. Uber has successfully ...
An edge gateway is an essential piece of infrastructure for large scale cloud-based services. In his session at 17th Cloud Expo, Mikey Cohen, Manager, Edge Gateway at Netflix, detailed the purpose, benefits and use cases for an edge gateway to provide security, traffic management and cloud cross region resiliency. He discussed how a gateway can be used to enhance continuous deployment and help testing of new service versions and get service insights and more. Philosophical and architectural ap...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
Disruption, Innovation, Artificial Intelligence and Machine Learning, Leadership and Management hear these words all day every day... lofty goals but how do we make it real? Add to that, that simply put, people don't like change. But what if we could implement and utilize these enterprise tools in a fast and "Non-Disruptive" way, enabling us to glean insights about our business, identify and reduce exposure, risk and liability, and secure business continuity?
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
By 2021, 500 million sensors are set to be deployed worldwide, nearly 40x as many as exist today. In order to scale fast and keep pace with industry growth, the team at Unacast turned to the public cloud to build the world's largest location data platform with optimal scalability, minimal DevOps, and maximum flexibility. Drawing from his experience with the Google Cloud Platform, VP of Engineering Andreas Heim will speak to the architecture of Unacast's platform and developer-focused processes.
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
Chris Matthieu is the President & CEO of Computes, inc. He brings 30 years of experience in development and launches of disruptive technologies to create new market opportunities as well as enhance enterprise product portfolios with emerging technologies. His most recent venture was Octoblu, a cross-protocol Internet of Things (IoT) mesh network platform, acquired by Citrix. Prior to co-founding Octoblu, Chris was founder of Nodester, an open-source Node.JS PaaS which was acquired by AppFog and ...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
In today's enterprise, digital transformation represents organizational change even more so than technology change, as customer preferences and behavior drive end-to-end transformation across lines of business as well as IT. To capitalize on the ubiquitous disruption driving this transformation, companies must be able to innovate at an increasingly rapid pace.
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.